Category - Developments

Developments

Neurology publishes Mobia’s two-year VNS-REHAB data demonstrating sustained stroke recovery

Mobia Medical (NASDAQ: MOBI) has announced the publication of two-year follow-up data from the VNS-REHAB study in Neurology, the peer-reviewed journal of the American Academy of Neurology, demonstrating that...

July 15, 2026

Developments

Fractyl reports positive one-year REMAIN-1 weight maintenance data

Fractyl Health (NASDAQ: GUTS) has announced positive one-year results from its REMAIN-1 Midpoint Cohort reinforcing the potential of the Revita DMR System to be the first durable procedural therapy for post-GLP-1 weight...

July 15, 2026

Developments

Profound Medical’s Autonomous Robotics and Incisionless Surgery to Have Strong Presence at SRS2026

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) announced that its MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure will be highlighted in several presentations by leading physicians at the...

July 15, 2026

Developments

Myricx to be acquired by Novartis for $1.5B

Closely held Myricx Bio has announced that it has reached an agreement to be acquired by Novartis (NYSE: NVS) for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments. The acquisition...

July 14, 2026

Developments

USPTO grants Immutep new patent for eftilagimod alfa combined with PD-1 pathway inhibitors

Immutep (ASX: IMM; NASDAQ: IMMP) has announced that the United States Patent and Trademark Office (USPTO) granted a new patent for eftilagimod alfa in combination with a PD-1 pathway inhibitor for the treatment of...

July 14, 2026

Developments

Envoy reports improvement in speech perception in trial of cochlear implant

Envoy Medical (NASDAQ: COCH) has announced positive 12-month data from the first ten participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant...

July 14, 2026

Developments

Valion advances integrated biodefense, immunology platform

Valion Bio (NASDAQ: VBIO) has provided an update for its Entolimod program—including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated...

July 14, 2026

Developments

VERAXA, Ardigen launch drug discovery collaboration

VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with closely held AI partner Ardigen to support VERAXA’s growing BiTAC pipeline of T-cell engagers and antibody-drug conjugates. According to VERAXA, the...

July 13, 2026

Developments

Virax signs immune profiling product supply deal with Fosun

Virax Biolabs (NASDAQ: VRAX) has announced the signing of an exclusive commercial supply agreement with Fosun Diagnostics, a subsidiary of Fosun Pharma (600196.SS; 02196.HK), for its research-use-only ImmuneSelect...

July 13, 2026

Developments

FDA grants RPD to Thiogenesis’ TTI-0102 for Leigh syndrome

Thiogenesis Therapeutics (TSXV: TTI; OTCQX: TTIPF) has announced that the FDA has granted Rare Pediatric Disease (RPD) designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. Upon approval of a...

July 13, 2026

Category - Developments

Subscribe